Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. by Sharp, A et al.
The Journal of Clinical Investigation C L I N I C A L  M E D I C I N E
1 9 2 jci.org   Volume 129   Number 1   January 2019
BACKGROUND. Liquid biopsies have demonstrated that the constitutively active androgen receptor splice variant-7 (AR-V7) 
associates with reduced response and overall survival from endocrine therapies in castration-resistant prostate cancer 
(CRPC). However, these studies provide little information pertaining to AR-V7 expression in prostate cancer (PC) tissue. 
METHODS. Following generation and validation of a potentially novel AR-V7 antibody for IHC, AR-V7 protein expression 
was determined for 358 primary prostate samples and 293 metastatic biopsies. Associations with disease progression, full-
length androgen receptor (AR-FL) expression, response to therapy, and gene expression were determined.
RESULTS. We demonstrated that AR-V7 protein is rarely expressed (<1%) in primary PC but is frequently detected (75% 
of cases) following androgen deprivation therapy, with further significant (P = 0.020) increase in expression following 
abiraterone acetate or enzalutamide therapy. In CRPC, AR-V7 expression is predominantly (94% of cases) nuclear and 
correlates with AR-FL expression (P ≤ 0.001) and AR copy number (P = 0.026). However, dissociation of expression was 
observed, suggesting that mRNA splicing remains crucial for AR-V7 generation. AR-V7 expression was heterogeneous 
between different metastases from a patient, although AR-V7 expression was similar within a metastasis. Moreover, 
AR-V7 expression correlated with a unique 59-gene signature in CRPC, including HOXB13, a critical coregulator of AR-
V7 function. Finally, AR-V7–negative disease associated with better prostate-specific antigen (PSA) responses (100% 
vs. 54%, P = 0.03) and overall survival (74.3 vs. 25.2 months, hazard ratio 0.23 [0.07–0.79], P = 0.02) from endocrine 
therapies (pre-chemotherapy).
CONCLUSION. This study provides impetus to develop therapies that abrogate AR-V7 signaling to improve our 
understanding of AR-V7 biology and to confirm the clinical significance of AR-V7.
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tumors using a potentially novel AR-V7 antibody. We establish 
that expression of AR-V7 protein is rare in primary PC. In addi-
tion, nuclear AR-V7 expression emerges in response to primary 
ADT alone in most patients, and further increases in response to 
AA or E therapy, with nuclear AR-V7 being an important marker 
of response to these endocrine therapies in CRPC. Furthermore, 
AR-V7 expression associates with AR-FL expression and AR copy 
number in CRPC, although many cases with high AR-FL protein 
expression have undetectable/low AR-V7 protein expression. 
Moreover, nuclear AR-V7 expression is heterogeneous in differ-
ent CRPC metastases in the same patient. Finally, nuclear AR-V7 
expression is associated with a unique gene signature in CRPC 
patients. These data support a critical role for AR-V7 in CRPC biol-
ogy and resistance to established endocrine therapies, providing 
further impetus for the development of therapeutic strategies that 
overcome AR-V7–mediated signaling to improve the outcome for 
patients with this lethal disease.
Results
Validation and optimization of a AR-V7 antibody (Clone RM7) for 
immunohistochemistry. A recombinant rabbit monoclonal antibody 
(Clone RM7) was developed, in collaboration with RevMAb Biosci-
ences, against CE3 of AR-V7. Antibody validation was performed at 
The Institute of Cancer Research/Royal Marsden Hospital (ICR/
RMH) and the University of Washington (UW). Western blot anal-
ysis of AR-V7–positive cell lines (LNCaP95, 22Rv1, and VCaP) 
demonstrated a strong AR-V7 band at 80 kDa (Figure 1A and Sup-
plemental Figure 1A; supplemental material available online with 
this article; https://doi.org/10.1172/JCI122819DS1). In contrast, 
no band was seen in AR-V7–negative cell lines (LNCaP, PC3, and 
DU145) at 80 kDa (Figure 1A and Supplemental Figure 1A). We 
next compared RM7 with EPR15656, an AR-V7 antibody that has 
been studied in PC tissue and circulating tumor cells (CTCs), and 
used for biomarker studies of treatment stratification in CRPC (27, 
28, 30). EPR15656 primarily recognizes AR-V7 but may also bind 
other proteins demonstrating staining in PC3 cells, colorectal (liv-
er) metastasis, normal lung epithelium, and cytoplasmic compart-
ment (2, 28, 30). EPR15656 demonstrated a strong AR-V7 band at 
80 kDa in LNCaP95, 22Rv1, and VCaP (Figure 1A and Supplemental 
Figure 1A). However, consistent with reports of positive staining in 
PC3 cells, EPR15656 demonstrated a strong band at 70 kDa in PC3 
(30). Following initial validation, specificity and increased affin-
ity (compared with EPR15656) of RM7 for AR-V7 was confirmed 
by immunoprecipitation using M12–cumate-inducible AR-V7 cells 
demonstrating a single band at 80 kDa (Figure 1B). RM7 detected 
additional bands at approximately 150 kDa and 32 kDa. However, 
both the strong 80-kDa AR-V7 band and the faint 32-kDa band dis-
appeared upon shRNA induction by doxycycline, suggesting that 
the 32-kDa band is a degradation product of AR-V7 (Figure 1C). In 
addition, the 150-kDa band was not seen by Western blot analysis 
using an alternative extraction method at UW (Figure 1C). Further-
more, when RM7 was optimized for immunohistochemistry (IHC), 
AR-V7–expressing cell lines (22Rv1, LNCaP95, and VCaP) were 
positive for AR-V7 by IHC and AR-V7–negative cell lines (LNCaP, 
DU145, and PC3) were negative for AR-V7, confirming that the 
150-kDa band (present in LNCaP) was not recognized by IHC 
and RM7 does not stain PC3 cells (Figure 1D). In addition, RM7 
Introduction
Prostate cancer (PC) is the most commonly diagnosed noncuta-
neous cancer and the second leading cause of male cancer-related 
death in the Western world (1). Androgen receptor (AR) signaling 
is critical for PC development and progression (2–5). PC patients 
with advanced disease after primary therapy respond robustly to 
androgen deprivation therapy (ADT), but nearly all will progress to 
fatal castration-resistant PC (CRPC). There is now mounting evi-
dence that progression to CRPC remains dependent on persistent 
AR signaling driven by increased androgen synthesis, overex-
pression of AR coactivators, AR amplification, and AR-activating 
point mutations (3, 5–9). These molecular findings have driven the 
development of new anti-androgen therapies, such as abiraterone 
acetate (AA), enzalutamide (E), and apalutamide, that target 
the AR axis in patients with castration-sensitive PC (CSPC) and 
CRPC. These therapies have led to improved patient outcomes 
and health-related quality of life (10–18).
Despite this significant progress, resistance to AA and E is com-
mon and on average occurs within a year of starting therapy; this is 
due, at least in part, to the emergence of constitutively active AR 
splice variants, of which AR splice variant-7 (AR-V7) is regarded as 
the most significant and most extensively characterized (19–31). 
AR-V7 is thought to arise from aberrant mRNA splicing of AR exons 
1–3, loss of exons 4–8, and inclusion of cryptic exon 3 (CE3) into 
the transcribed AR gene (22, 31). The resultant protein product is 
constitutively active in the absence of androgens and drives growth 
of PC cell lines and patient-derived xenografts in the presence 
of AR-directed therapies such as AA or E (23, 24, 31, 32). AR-V7 
forms homodimers with itself and heterodimers with full-length 
AR (AR-FL) and in the absence of androgens binds to AR response 
elements, facilitating the generation of a protumorigenic transcrip-
tome (33). In addition, transgenic mice with forced expression of 
AR-V7 display a protumorigenic phenotype (34). These preclinical 
studies confirm that AR-V7 may facilitate ligand-independent AR 
signaling to drive resistance to established endocrine therapies.
Insufficient data have been available on AR-V7 mRNA and 
protein expression in primary PC, although some studies suggest 
expression (35–38). AR-V7 protein expression increases as patients 
develop CRPC and resistance to AA or E (29–31, 39). A plethora of 
clinical studies have confirmed AR-V7 expression to be correlated 
with resistance to AA and E therapy in CRPC; the majority of these 
measured AR-V7 mRNA or protein from liquid biopsies (i.e., circu-
lating tumor cells, exosomes, or whole blood) as opposed to using 
metastatic tumor biopsies (19, 20, 26–30, 40–42). All clinically 
licensed therapies modulate AR activity through its ligand-bind-
ing domain and therefore conceptually have no activity against 
AR-V7–mediated oncogenic signaling. Pharmacological inhibitors 
of bromodomain and extraterminal proteins and HSP90 suppress 
AR-V7 generation through inhibition of mRNA splicing and inhibit 
the growth of CRPC models (32, 43, 44). However, these therapies 
target multiple cellular pathways, and therefore concerns with 
regard to clinical utility and safety remain. The development of 
novel therapies that overcome AR-V7 signaling in CRPC remains 
an area of urgent unmet clinical need.
In this work, we have performed an extensive cross-institu-
tional study to determine nuclear AR-V7 protein expression in 
tissue biopsies and autopsies from primary and metastatic PC 
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Primary prostate cancers rarely express AR-V7 protein. Previous 
studies have demonstrated AR-V7 mRNA and protein expression 
in primary PC (36–39). Having validated and optimized RM7 for 
IHC on PC patient samples, we investigated nuclear AR-V7 protein 
expression in early PC specimens. We used the ICR/RMH and 
UW CSPC cohorts (Figure 2). A single biopsy (1.6%) of 63 CSPC 
biopsies (ICR/RMH CSPC cohort) expressed nuclear AR-V7 (Fig-
ure 3B and Supplemental Table 1). Similarly, in 295 primary PC 
specimens (UW CSPC cohort) from men who were treated with 
a radical prostatectomy, and had not received AR-directed thera-
py, there were no (0%) nuclear AR-V7–positive cases (Figure 3C). 
stained neither a colorectal cancer (liver) metastasis nor normal 
lung epithelium, which stained positive with EPR15656 previously 
(Supplemental Figure 1B and ref. 30). Having confirmed that RM7 
recognizes AR-V7, we performed IHC on formalin-fixed, paraf-
fin-embedded PC patient tissue biopsies within our study cohorts, 
demonstrating strong, almost exclusively, nuclear staining (Figure 
2 and Figure 3A). In contrast, EPR15656 demonstrated cytoplasmic 
staining in PC tissue and CTCs (27, 28, 30). Taken together, these 
data demonstrate that RM7 specifically recognizes AR-V7 protein 
in tissue biopsies from PC patients, with reduced off-target liabili-
ties compared with EPR15656.
Figure 1. Validation and optimization of a potentially novel AR-V7 antibody (Clone RM7) for immunohistochemistry. (A) Western blot (long exposure) of 
AR-V7–positive (LNCaP95, 22Rv1, and VCaP) and –negative (LNCaP, PC3, and DU145) PC cell lines using a novel recombinant rabbit monoclonal anti–AR-V7 
antibody (Clone RM7) and a previously reported anti–AR-V7 antibody (EPR15656). All cell lines except LNCaP95 (10% charcoal-stripped serum) were grown 
in 10% FBS. (B) Immunoprecipitation of AR-V7 from M12–cumate-inducible AR-V7 cells using the same concentration of AR-V7 antibodies and Western 
blot performed with AR N-terminal domain (AR-NTD) antibody. (C) LNCaP95 cells with doxycycline-inducible shRNA to AR-V7 were treated with (or with-
out) doxycycline and Western blot performed with AR-V7 antibody (RM7). (D) Micrographs of AR-V7 detection by IHC using AR-V7 antibody (RM7) in cell 
line pellets positive (22Rv1, LNCaP95, and VCaP) and negative (LNCaP, DU145, and PC3) for AR-V7 (original magnification, ×200; scale bar: 50 μm).
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or E therapy. Having demonstrated that nuclear AR-V7 protein is 
infrequently expressed in CSPC, we next explored nuclear AR-V7 
expression in same-patient, matched biopsies, as 63 patients pro-
gressed from CSPC to CRPC (Figure 2). Nuclear AR-V7 protein 
significantly (P < 0.001) increased from CSPC (median H score, 
interquartile range [IQR]: 0, 0–0) to CRPC (H score, IQR: 70, 
5–130) (Figure 3B). Next, we expanded this cohort to 160 CRPC 
biopsies (Figure 2). Median nuclear AR-V7 expression was (H 
score) 75, (IQR) 5–130 (Figure 3D and Supplemental Table 3); 
three (1.9%) metastatic CRPC (mCRPC) biopsies of 160 cases had 
Clinical data (for prostate-specific antigen progression–free sur-
vival) were available on 128 patients from the UW CSPC cohort 
(Supplemental Table 2). Of the 128 patients with 5-year follow-up, 
64 had biochemical recurrence; none of these 64 patients had 
detectable AR-V7 protein in their initial prostatectomy tissue. 
These data confirm that AR-V7 is rarely (0.3%; 1 of 358) expressed 
and therefore nuclear AR-V7 protein expression cannot predict 
disease recurrence in radically treated primary PC.
AR-V7 protein emerges as PC patients and mouse xenografts 
progress to castration-resistant disease and develop resistance to AA 
Figure 2. Summary of clinical samples analyzed. Overview of the ICR/RMH, UW, and SU2C/PCF patient cohorts utilized for this study. The ICR/RMH 
patient cohort included 63 CSPC biopsies and 160 CRPC biopsies stained for nuclear AR-V7 expression. Of the 160 biopsies with AR-V7 expression, AR-FL 
expression was available in 144 biopsies, AR copy number in 95, and RNA-Seq in 21. Response data were available for AA or E before chemotherapy in 36 
patients, AA or E after chemotherapy in 54 patients, and docetaxel chemotherapy in 55 patients. The UW patient cohort included 295 CSPC tissues (from 
295 patients) who had radical prostatectomy as primary therapy and 133 CRPC biopsies of metastases (from 34 patients). Of 133 CRPC biopsies from 34 
patients with AR-V7 expression, RNA-Seq was available in 41 biopsies. The SU2C/PCF patient cohort included 122 CRPC biopsies with RNA-Seq analysis.
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nificantly lower (P = 0.020) in 40 biopsies prior to AA or E ther-
apy (H score, IQR: 40, 1–107.5) than in 120 biopsies after AA or 
E therapy (H score, IQR: 90, 20–150) (Figure 3D). There was no 
clear association between nuclear AR-V7 expression and time of 
biopsy after starting of AA or E therapy (r = –0.11 [–0.31 to 0.09], 
P = 0.27) (Supplemental Figure 2). Next we determined whether 
nuclear AR-V7 expression differed between sites of CRPC biopsy. 
Nuclear AR-V7 expression was higher (P = 0.013) in lymph node 
metastases (H score, IQR: 120, 60–170) compared with bone 
neuroendocrine-like features and were negative for both nucle-
ar AR-FL and nuclear AR-V7 expression. We next determined 
whether nuclear AR-V7 expression altered as patients progressed 
through standard-of-care AR-targeting therapies for CRPC (Fig-
ure 3D). Interestingly, 15 (75%) of 20 biopsies taken after progres-
sion on primary ADT (with or without bicalutamide) before the 
starting of standard systemic therapy for CRPC had detectable 
nuclear AR-V7 protein expression (H score, IQR: 40, 1.25–92.5) 
(Figure 3D). Furthermore, nuclear AR-V7 expression was sig-
Figure 3. AR-V7 protein expression in PC. (A) Representative micrographs of AR-V7 detection by IHC in 4 ICR/RMH patients with matched CSPC and CRPC 
biopsies (original magnification, ×200; scale bar: 50 μm). Prostate (Prostate Bx), prostatectomy, transurethral resection of the prostate (TURP), lymph 
node (LN), and bone marrow trephine (BMT) biopsies are shown. (B) Nuclear AR-V7 expression (H score [HS]) in 63 same-patient matched CSPC (gray) 
and CRPC (red) biopsies from the ICR/RMH cohort. Three AR-null CRPC cases with neuroendocrine features are shown (blue). Median HS and interquar-
tile range are shown. P value was calculated using Wilcoxon signed-rank test. (C) Nuclear AR-V7 expression (HS) in 295 prostatectomy samples before 
any AR-targeted therapy. Median HS and interquartile range are shown. (D) Nuclear AR-V7 expression (HS) in 160 CRPC biopsies (red) and dichotomized 
(orange) by before (40 biopsies) and after (120 biopsies) AA or E treatment. Three AR-null CRPC cases with neuroendocrine features are shown (blue). 
Twenty biopsies taken after progression on primary ADT (with or without bicalutamide) and prior to standard therapy for CRPC are shown (green). Median 
HS and interquartile range are shown. P value was calculated using Mann-Whitney test. (E) Nuclear AR-V7 expression (HS) in 160 CRPC biopsies (red) from 
lymph node (LN), bone (BMT), liver, prostate, and other sites of metastases. Three AR-null CRPC cases with neuroendocrine features are shown (blue). 
Median HS and interquartile range are shown. P value was calculated using nonparametric equality-of-medians test.
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(H score, IQR: 50, 1–110), liver (H score, IQR: 70, 3.75–132.5), pros-
tate (H score, IQR: 50, 0–70), and other (H score, IQR: 90, 0–150) 
sites of metastases (Figure 3E). Finally, we investigated whether 
the same pattern of nuclear AR-V7 expression was observed as 
VCaP (androgen-dependent) mouse xenograft models developed 
therapeutic resistance. Consistent with our tissue studies, nucle-
ar AR-V7 expression increased in VCaP mouse xenografts as they 
progressed from the castration-sensitive (H score, IQR: 0, 0–0) 
to the castration-resistant state (H score, IQR: 155, 102.5–175) to 
AA/E resistance (H score, IQR: 180, 160–190) (Supplemental Fig-
ures 3 and 4). Although nuclear AR-V7 protein is rarely expressed 
in primary PC, AR-V7 protein expression emerges as patients and 
mouse xenografts progress to castration-resistant disease, and 
levels increase further as resistance to AA or E therapy develops.
AR-V7 protein expression associates with response to AA and E, 
but not docetaxel, in CRPC. Studies have shown AR-V7 protein and 
mRNA to be a marker of next-generation AR-targeted therapy 
(AA and E) resistance (19, 20, 26–30). To investigate this further, 
we determined the response of the ICR/RMH CRPC cohort to 
AR-targeted therapies before and after chemotherapy in AR-V7–
negative (nuclear H score ≤ 10) and AR-V7–positive (nuclear H 
score > 10) patients. Thirty-six patients received AA or E for CRPC 
prior to chemotherapy and had fully evaluable response data 
(Figure 2). Patients negative for AR-V7 
expression were younger (P = 0.04) at 
the time of starting AR-targeting ther-
apy before chemotherapy, but no other 
differences in baseline characteristics 
were observed (Table 1). Patients neg-
ative for AR-V7 (n = 8) had a greater 
prostate-specific antigen (PSA) 50% 
nadir (100% vs. 68%, P = 0.16) and 
PSA 50% response rate (100% vs. 54%, 
P = 0.03) than AR-V7–positive patients 
(n = 28) (Figure 4, A and B). Patients 
achieving a 50% PSA fall had signifi-
cantly lower (P = 0.012) nuclear AR-V7 
expression (H score, IQR: 40, 0–100) 
than those who did not (H score, IQR: 
120, 55–180) (Supplemental Figure 5). 
Furthermore, AR-V7–negative patients 
had a longer time to PSA progression 
(11.5 vs. 4.8 months, hazard ratio [HR] 
0.33 [0.14–0.81], P = 0.02), longer time 
to clinical/radiological progression 
(13.9 vs. 7.2 months, HR 0.47 [0.20–
1.10], P = 0.08), and improved overall 
survival (74.3 vs. 25.2 months, HR 0.23 
[0.07–0.79], P = 0.02) (Figure 4, C–E). 
Fifty-four patients received AA or E for 
CRPC after chemotherapy and had ful-
ly evaluable response data (Figure 2). 
There were no differences in the base-
line characteristics by AR-V7 status at 
the time of starting AR-targeting ther-
apy after chemotherapy (Supplemental 
Table 4). Patients negative for AR-V7 
(n = 17) had a significantly greater PSA 50% nadir (71% vs. 24%, 
P = 0.002) and PSA 50% response rate (59% vs. 22%, P = 0.012) 
than those positive for AR-V7 (n = 37) (Supplemental Figure 6, A 
and B). Patients achieving a 50% PSA fall had significantly low-
er (P = 0.011) nuclear AR-V7 expression (H score, IQR: 3, 0–80) 
than those who did not (H score, IQR: 95, 25–125) (Supplemental 
Figure 6C). Interestingly, despite these significant differences in 
response rates, there was no significant difference in time to PSA 
progression (2.8 vs. 2.3 months, HR 0.96 [0.54–1.73], P = 0.90), 
time to clinical/radiological progression (4.9 vs. 5.1 months, HR 
0.92 [0.51–1.66], P = 0.77), or overall survival (14.0 vs. 15.7 months, 
HR 1.01 [0.56–1.82], P = 0.98) (Supplemental Figure 6, D–F). Hav-
ing explored response to AR-targeted therapy, we next investigat-
ed response to docetaxel chemotherapy. Fifty-five patients were 
treated with docetaxel chemotherapy for CRPC and had fully 
evaluable response data (Figure 2). There was no evidence of a dif-
ference in baseline characteristics at the time of starting docetaxel 
chemotherapy (Supplemental Table 5). In contrast to AR-target-
ing therapies, there was no difference in PSA 50% nadir (56% vs. 
46%, P = 0.57) and PSA 50% response rate (39% vs. 27%, P = 0.54) 
between AR-V7–negative (n = 18) and –positive patients (n = 37) 
(Supplemental Figure 7, A and B). Nuclear AR-V7 expression was 
not significantly (P = 0.14) different in patients achieving a 50% 
Table 1. Baseline characteristics at start of AR-targeting therapy (before chemotherapy)
AR-V7 negative (H score ≤10) AR-V7 positive (H score >10) P value
N = 8 N = 28
Age (years), mean (SD) 63.0 (4.8) 69.0 (7.5) 0.04A
Performance status, N (%)
0 4 (50) 14 (50)
1 4 (50) 14 (50) 1.00B
2 0 (0) 0 (0)
>2 0 (0) 0 (0)
Blood
Hb (g/l), mean (SD) 133.0 (8.7) 127.6 (12.2) 0.25A
ALT (U/l), mean (SD) 21.4 (6.1) 22.0 (8.5) 0.84A
ALP (U/l), median (IQR) 90.0 (80.3–170.5) 90.0 (63.5–176.8) 0.83C
Albumin (g/l), mean (SD) 36.5 (2.9) 38.4 (3.3) 0.16A
LDH (U/l), median (IQR) 163.0 (144.0–169.0)D 168.0 (156.0–184.0)D 0.29C
PSA (ng/ml), median (IQR) 154.0 (8.9–238.3) 87.5 (35.5–272.5) 0.62C
Metastatic, N (%)
Node only 3 (38) 4 (14)
Visceral (with/without bone) 1 (13) 1(4) 0.12B
Bone 4 (50) 23 (82)
AR therapy, N (%)
Abiraterone 5 (63) 19 (68) 1.00B
Enzalutamide 3 (38) 9 (32)
Prior CRPC treatments, N (%)
Abiraterone 0 (0) 0 (0) NA
Enzalutamide 0 (0) 0 (0)
Docetaxel 0 (0) 0 (0)
Cabazitaxel 0 (0) 0 (0)
ALP, alkaline phosphatase; ALT, alanine aminotransferase; Hb, hemoglobin; IQR, interquartile range; LDH, 
lactate dehydrogenase; NA, not applicable; PSA, prostate-specific antigen. At test; BFisher’s exact test; 
Crank-sum test; D1 patient missing LDH value.
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PSA fall with docetaxel (H score, IQR: 20, 0–85) compared with 
those who did not (H score, IQR: 70, 5–132.5) (Supplemental Fig-
ure 7C). Consistent with this, there was no significant difference in 
time to PSA progression (4.8 vs. 4.7 months, HR 1.04 [0.57–1.92], 
P = 0.90) and time to clinical/radiological progression (6.9 vs. 7.5 
months, HR 1.31 [0.73–2.34], P = 0.36) (Supplemental Figure 7, D 
and E). However, AR-V7–negative patients had improved overall 
survival (26.3 vs. 18.5 months, HR 0.50 [0.27–0.95], P = 0.03) 
compared with AR-V7–positive patients (Supplemental Figure 7F). 
Taken together, these data confirm that AR-V7 is a robust prog-
nostic biomarker and an important indicator of sensitivity to AR- 
targeted therapies but not docetaxel treatment in CRPC.
Figure 4. AR-V7 status and response to AR-targeting therapies (AA or E) prior to chemotherapy in CRPC. Thirty-six patients received AR-targeting ther-
apies (AA or E) prior to chemotherapy for CRPC. (A) Percentage PSA nadir on AR-targeting therapies for AR-V7–negative (H score ≤ 10; gray) and AR-V7–
positive (H score > 10; red) CRPC patients is shown. Fifty percent PSA nadir rate is shown. P value was calculated using Fisher’s exact test. (B) Percentage 
12-week 50% PSA response rate on AR-targeting therapies for AR-V7–negative (gray) and AR-V7–positive (red) CRPC patients is shown. Twelve-week 50% 
PSA response rate is shown. P value was calculated using Fisher’s exact test. (C–E) Kaplan-Meier curves show time to PSA progression (C), time to clinical/
radiological progression (D), and overall survival (E) from start of AR-targeting therapy. Hazard ratios (HRs) with 95% confidence intervals (CIs) are shown. 
P value was calculated using univariate Cox proportional hazards model.
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Figure 5. AR-FL and AR-V7 mRNA and protein quantification with AR copy number analysis in CRPC. (A) AR-FL and AR-V7 mRNA expression in frag-
ments per kilobase of transcript per million mapped reads (FPKM) for 122 CRPC transcriptomes from the SU2C/PCF cohort is shown. Spearman’s rank 
correlation is shown. (B) Expression (H score [HS]) for nuclear, cytoplasmic, and total (nuclear + cytoplasmic) AR-V7 (gray) and AR-FL N-terminal domain 
(NTD; red) is shown. Median HS and interquartile range are shown. (C) Expression (HS) of total AR-FL NTD protein and total AR-V7 protein in 144 CRPC 
biopsies from the ICR/RMH CRPC cohort is shown. Spearman’s rank correlation is shown. (D) Expression (HS) of total AR-FL NTD protein and AR copy 
number (log2) in 95 CRPC biopsies from the ICR/RMH CRPC cohort are shown. Cases with AR mutations are shown (L702H gray, T878A green, H875Y pur-
ple, K313E yellow). Spearman’s rank correlation is shown. (E) Expression (HS) of total AR-V7 protein and AR copy number (log2) in 95 CRPC biopsies from 
the ICR/RMH CRPC cohort are shown. Cases with AR mutations are shown. Spearman’s rank correlation is shown. (F) Expression (HS) of nuclear AR-FL 
NTD protein and nuclear AR-V7 protein in 144 CRPC biopsies from the ICR/RMH CRPC cohort is shown. Spearman’s rank correlation is shown.
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(RNA-Seq) data obtained from 122 CRPC biopsies demonstrated 
that AR-FL mRNA expression significantly correlated with AR-V7 
mRNA expression (r = 0.69 [0.58–0.77], P ≤ 0.001) (Figure 5A). 
In light of RNA quantification not discriminating against cellular 
localization, we next quantified total (nuclear and cytoplasmic) 
AR-FL and AR-V7 protein expression in 144 CRPC biopsies (ICR/
RMH CRPC cohort) (Figure 5B and Supplemental Figure 8). Unlike 
AR-FL and AR-V7 mRNA and protein expression associate in a 
high proportion of, but not all, CRPCs. We and others have shown 
that AR-FL and AR-V7 mRNA and protein are induced upon castra-
tion, and that therapies suppressing mRNA splicing prevent AR-V7 
mRNA and protein generation in CRPC (33, 44–47). Therefore, we 
next investigated the association between AR-FL and AR-V7 mRNA 
and protein expression (Figure 2). Analysis of RNA sequencing 
Figure 6. AR-V7 protein expression variability within metastasis and between 
metastases from individual patients with CRPC. (A) Representative micro-
graphs of AR-V7 detection by IHC in 4 UW patients with multiple CRPC biopsies 
(original magnification, ×200; scale bar: 50 μm). (B) Nuclear AR-V7 expression 
(OD) in 133 metastases from 34 CRPC patients from the UW CRPC cohort. Mean 
OD and standard deviation (SD) for 3 measurements from each metastasis are 
shown. Each box encloses all metastases from a patient. Different colors for 
each patient represent an individual metastasis. (C) Frequency distribution of 
SD within a metastasis (Intratumor; comparison of triplicates in a metasta-
sis; red) and between metastases (Between-tumor; comparison of multiple 
metastasis within a patient; blue) is shown. Median SD is 1.2 for intratumor 
measurements and 2.9 for between-tumor measurements.
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demonstration that AR-FL and AR-V7 are differentially localized, 
there was no significant correlation between nuclear AR-FL and 
nuclear AR-V7 protein expression in 144 CRPC biopsies from the 
ICR/RMH CRPC cohort (r = 0.11 [–0.06 to 0.27], P = 0.20) (Figure 
5F). These data demonstrate that, taken together, total AR-FL and 
AR-V7 mRNA and protein expression correlate in CRPC biopsies, 
although, importantly, many patients have tumors expressing high 
levels of AR-FL mRNA and protein but that have low or undetect-
able AR-V7 mRNA and protein expression. This suggests that the 
presence of AR-V7 mRNA and protein is not simply a consequence 
of higher AR-FL levels in all cases.
AR-V7 protein expression is largely homogenous within metasta-
sis but heterogeneous between metastases from patients with CRPC. 
AR-FL, of which 124 of 144 (86%) biopsies had both cytoplasmic 
and nuclear AR-FL protein expression, AR-V7 protein was almost 
exclusively (136/144; 94% of biopsies) nuclear in localization (Fig-
ure 5B). There was a significant correlation between total AR-FL 
and AR-V7 protein expression in 144 CRPC biopsies from the ICR/
RMH CRPC cohort (r = 0.28 [0.11–0.42], P ≤ 0.001) (Figure 5C). 
However, it is important to recognize that a substantial number 
of patients with high AR-FL mRNA and protein expression had 
low or undetectable levels of AR-V7 mRNA and protein. Further-
more, both total AR-FL (r = 0.46 [0.28–0.61], P ≤ 0.001) and total 
AR-V7 (r = 0.23 [0.02–0.42], P = 0.026) protein significantly cor-
related with AR copy number in 95 CRPC biopsies from the ICR/
RMH CRPC cohort (Figure 5, D and E). Finally, consistent with the 
Figure 7. AR-V7 protein expression is associated with a unique gene signature in metastatic CRPC. (A) Expression (OD) of nuclear AR-V7 protein correlat-
ed (q < 0.05) with gene mRNA expression of 487 (407 upregulated and 80 downregulated) genes in 41 metastases from 24 patients from the UW CRPC 
cohort. Heatmap shows metastases ranked in order of nuclear AR-V7 expression (OD) and mean-centered log2 fold change in gene mRNA expression. (B) 
Fifty-nine of the 407 upregulated genes were validated in either 21 CRPC metastases from the ICR/RMH CRPC cohort or 122 CRPC transcriptomes from  
the SU2C/PCF cohort. Figure shows overlap of significantly correlated genes between the 3 cohorts. (C) Heatmap shows metastases ranked in order of 
nuclear AR-V7 expression (OD) and mean-centered log2 fold change in gene mRNA expression of the 59-gene signature in the UW CRPC cohort (n = 41).  
(D) Pathway overrepresentation analysis using MSigDB v6.2 (H, Hallmark; CP, Canonical Pathways; C4, Computational Gene Sets; C5, GO; and C6, Oncogenic 
Pathway) in the 59-gene set. Pathways with FDR less than 0.05 are shown. GSEA, gene set enrichment analysis.
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progression (Supplemental Table 9 and refs. 52–64). In addition, 
genome-wide analyses demonstrated that AR-V7 protein expres-
sion associates with AR gene expression (Figure 7C). Although 
an association between AR-FL mRNA and AR-V7 mRNA using 
junction-specific reads was confirmed, there was further confir-
mation that a substantial number of cases that express high AR-FL 
mRNA levels have low or undetectable AR-V7 mRNA (Supplemen-
tal Figure 11). These data suggest that AR-V7 expression is asso-
ciated with a specific gene signature in a large patient population 
that may play a key role in transcriptional activity and PC progres-
sion in patients with CRPC.
Discussion
Since the pioneering studies of Huggins and Hodges in 1941, the 
androgen receptor has remained the focus of therapeutic targeting 
in CRPC. Inhibition of the AR axis with AA and E has improved 
both overall survival and quality of life for patients with CRPC 
(10–17, 65). Although these modalities are initially effective, resis-
tance develops with ongoing AR activity and tumor progression. 
This is, at least in part, due to the expression of constitutively 
active AR splice variants, of which AR-V7 appears to be the most 
common (19–32). AR-V7 mRNA and protein expression has been 
detected at low levels in primary, treatment-naive PC, and studies 
have reported a potential association with worse outcome (36–39). 
Surprisingly, in 2 separate patient cohorts we found that nuclear 
AR-V7 protein was expressed in fewer than 1% of PC tumors at 
diagnosis, and therefore it cannot be predictive of outcome after 
primary therapy. The difference in prevalence of AR-V7 protein 
expression reported in different studies is likely attributable to the 
different AR-V7 antibodies used, and in particular, the observation 
that one antibody used has off-target liabilities as we have previ-
ously reported (30). Consistent with this, we demonstrate AR-V7 
protein expression to be almost exclusively nuclear, whereas pre-
vious studies have demonstrated cytoplasmic positivity (27, 28, 
30). These data suggest that AR-V7 testing is unlikely to be of use 
for treatment stratification at time of diagnosis and may be better 
utilized beyond first-line treatment (11, 18).
In contrast to primary PC, 75% of CRPC patients who had 
progressed on primary ADT alone (with or without bicalutamide) 
expressed nuclear AR-V7 before receiving AA or E. Despite AR-V7 
expression after primary ADT, subsequent AA or E treatment has 
significant antitumor activity with response rates ranging from 
57% to 78% (12, 14, 66). These data indicate that AR-V7 protein 
expression in biopsies cannot indicate absolute refractoriness to 
treatment. Although, consistent with previous reports, nuclear 
AR-V7 levels increased further in response to AA or E, these data 
suggest that AR-V7 expression is a factor at the initial phase of 
castration resistance following primary ADT in advanced PC (30, 
40). These data were further confirmed in VCaP mouse xeno-
graft models as they developed resistance to castration and AA/E 
therapy. Recent studies have shown AA therapy at diagnosis to 
improve overall survival in PC patients with de novo metastatic 
disease (11, 18). The demonstration that nuclear AR-V7 expres-
sion is rare in primary PC, but emerges with primary therapy, may 
provide insight into the greater efficacy of AA in CSPC. Impor-
tantly, these data show that increased AR-V7 expression is an ear-
ly event in resistance, and if agents targeted to AR splice variants 
We have previously shown that in a patient with a genomic rear-
rangement resulting in the constitutively active ARv567es variant, 
each of 5 metastases expressed the variant AR in a homogenous 
fashion (48). Since AR-V7 is usually generated not from a structur-
al rearrangement of the AR gene but rather from aberrant mRNA 
splicing, we next quantitated expression in 133 metastases from 
34 CRPC patients that were collected as part of the University of 
Washington Medical Center Prostate Cancer Donor Rapid Autopsy 
Program (UW CRPC cohort) (Figure 2, Figure 6A, and Supplemen-
tal Table 6). Automated digital scoring reported as optical density 
(OD) correlated significantly (r = 0.86 [0.83–0.89], P ≤ 0.001) with 
manual scoring and was used to determine nuclear AR-V7 expres-
sion in the UW CRPC cohort (Supplemental Figure 9, A–C). Three 
tissue microarray spots were stained from each metastasis and 
AR-V7 levels quantified. We found that expression of AR-V7 was 
largely consistent within each metastasis from a patient and that 
the variance was not statistically significant (Fligner-Killeen P = 
0.9999, Levene’s P = 0.9972) (Figure 6, B and C). However, expres-
sion of AR-V7 in different metastases in an individual patient dif-
fered widely, and the variance was statistically significant (Fligner- 
Killeen P = 3.73 × 10–06, Levene’s P = 3.25 × 10–07) (Figure 6, B and 
C). These data suggest that within an individual patient the degree 
to which AR-V7 may be driving different metastases varies and 
may result in mixed response to endocrine therapies.
AR-V7 expression is associated with a unique gene signature in 
CRPC. Having demonstrated interpatient and intrapatient hetero-
geneity in nuclear AR-V7 expression, we next investigated wheth-
er nuclear AR-V7 expression was associated with a specific gene 
signature in CRPC patients. Forty-one metastatic biopsies from 24 
men within the UW CRPC cohort had mRNA expression (RNA-
Seq) and AR-V7 protein expression (IHC) available. The correla-
tion between AR-V7 protein expression (OD) and gene mRNA 
expression (log2 counts per million) was determined and corrected 
for multiple testing. We identified 487 genes that correlated (q < 
0.05) with AR-V7 protein expression; of these, 407 positively cor-
related and 80 negatively correlated (Figure 7A). Pathway analy-
sis of the 407 genes that positively correlated with AR-V7 protein 
expression identified an enrichment for pathways involved in 
transcription and the androgen response (Supplemental Figure 
10, Supplemental Table 7, and refs. 49, 50). We confirmed that 
AR-V7 mRNA expression and AR-V7 protein expression correlated 
significantly in 41 UW (P < 0.001) and 21 ICR/RMH (P = 0.004) 
CRPC biopsies (data not shown). Next we independently tested 
the positively correlated 407-gene signature in 21 CRPC metas-
tases from an ICR/RMH CRPC cohort and 122 CRPC tumor 
transcriptomes (International Stand Up To Cancer/Prostate Can-
cer Foundation [SU2C/PCF] cohort) (Supplemental Table 8 and 
ref. 51). Of the genes identified, 59 were found to be significant-
ly correlated with nuclear AR-V7 protein expression in the ICR/
RMH cohort or with AR-V7 mRNA expression in the SU2C/PCF 
cohort (Figure 7, B and C, and Supplemental Table 9). Following 
this, pathway analysis of the 59 independently validated genes 
confirmed a role in transcriptional activity (Figure 7D and Supple-
mental Table 10). Consistent with this finding, 33% were zinc fin-
ger–containing (ZNF) genes correlated with chromatin binding, 
including HOXB13, ELL2, STEAP2, and BAZ2A. Furthermore, a 
large number of the genes identified have been associated with PC 
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AR-V7 expression associate in CRPC, a substantial number of 
patients with high levels of AR-FL demonstrate undetectable or 
low levels of AR-V7 expression. In keeping with this also is evi-
dence emerging that therapies that suppress mRNA splicing 
decrease AR-V7 generation in CRPC models (33, 45). JMJD1A has 
recently been reported to be critical for mRNA splicing and AR-V7 
generation but does not impact on AR-FL levels (77). These data 
suggest that mRNA splicing is important for AR-V7 generation 
and is not simply a consequence of increased AR-FL expression. 
Further understanding of the mechanisms underpinning AR-V7 
generation are now required to support the development of ther-
apeutic strategies to suppress splice variant generation in CRPC.
Previous studies examining AR-V7 cistromes and transcrip-
tomes demonstrated proliferative cistomes/transcriptomes that 
are likely not specific to AR-V7 but a marker of rapidly progres-
sive disease (23, 78–80). Although a recent study suggested that 
CRPC transcriptomes are diverse, we identified 59 genes using 
3 independent patient cohorts that associate with AR-V7 expres-
sion (79). One important consideration is that AR-V7 protein 
expression associates with AR gene expression in genome-wide 
analysis. However, as both AR-V7 and AR-FL mRNA would be 
represented in such studies, further junction-specific quantifi-
cation was performed. Despite this approach confirming a cor-
relation between AR-FL and AR-V7 mRNA, there was further evi-
dence of dissociation in many cases. In addition, a gene signature 
was derived from AR-V7 protein expression; unlike AR-FL pro-
tein, AR-V7 is almost exclusively nuclear, and therefore, unlike 
mRNA analysis, this takes into consideration its likely function-
al importance. Interestingly, BAZ2A, SRC, STEAP1, STEAP2, 
DCAF6, TMBIM6, HOXB13, GALANT7, WWC1, SPATS2, and 
GSTP1 expression associated with AR-V7 expression, and all of 
these have been previously linked to PC progression (52–64). 
In addition, HOXB13 has recently been shown to be critical for 
AR-V7 chromatin binding (79). Furthermore, we found a number 
of ZNF contigs to be associated with AR-V7 expression, provid-
ing evidence of increased transcriptional activity. These data 
suggest that AR-V7 protein expression is associated with a unique 
gene signature important for PC progression and transcriptional 
activity. It is important to stress that the 59-gene set derived does 
not represent the AR-V7 cistrome but is a set of genes associated 
with AR-V7 expression between cohorts and may identify com-
mon characteristics of AR-V7–associated disease. Components of 
this gene signature, including HOXB13, which has recently been 
shown to be critical for AR-V7 function, may provide insight into 
therapeutic targets for novel treatment strategies in patients with 
high levels of AR-V7 expression (79).
In conclusion, our results show that AR-V7 protein expression, 
using a validated, highly specific antibody, is not seen in primary 
CSPC and does not appear until initial resistance to standard ADT 
occurs, and increases further with AA and E therapy. In addition, 
AR-V7 protein expression associates with resistance to AR-targeted 
therapies but not taxane treatment in patients with CRPC. Fur-
thermore, although AR-V7 and AR-FL expression levels associ-
ate in CRPC, there are many cases in which expression levels are 
uncoupled, suggesting that AR-V7 protein expression is not simply 
a function of AR-FL protein expression. Moreover, AR-V7 protein 
is heterogeneously expressed, especially between metastases 
become clinically available, therapy may need to be combined at 
the time of initial ADT.
Critically, we found that AR-V7 protein expression is more 
prevalent in CRPC biopsies than previously reported from 
AR-V7 mRNA and protein expression studies in liquid biopsies 
(11%–46%) (19, 20, 27–29). This important observation is like-
ly due to the differences in sensitivities of the assays used. In 
addition, CRPC biopsies demonstrate lymph node metastases to 
express higher levels of AR-V7 than other sites of disease, which 
may (depending on the source of CTCs) account for the low-
er incidence of AR-V7 detected in liquid biopsies. Furthermore, 
we demonstrate intrapatient heterogeneity of nuclear AR-V7 
expression between multiple metastases, indicating that this is a 
further potential source of variation in CTC-based AR-V7 assess-
ment. Finally, depending on the biomarkers used to select CTCs, 
assessment of AR-V7 may be underestimated if not all CTCs are 
identified. These findings suggest that the detection of AR-V7 in 
CTCs may not be representative of all metastases, and that while 
sites of disease expressing AR-V7 may be resistant to current 
endocrine therapies, those expressing low AR-V7 or no AR-V7 
may still respond, within the same subject. Additional studies 
focusing on the prognostic value of tissue-based AR-V7 detection 
in CTC-negative patients may be warranted.
The majority of clinical studies have demonstrated that AR-V7 
positivity confers resistance and poorer outcome to AR-targeting 
therapies in patients with CRPC (19, 20, 26–31). We confirmed 
that AR-V7–positive patients treated with AA or E had a worse 
PSA response rate in the pre- and post-chemotherapy setting; and 
those patients who responded had lower levels of AR-V7 expres-
sion. Interestingly, despite poorer response rates, only AR-V7–pos-
itive patients treated with AA or E before chemotherapy had short-
er progression-free and overall survival. This observation could be 
multifactorial. Firstly, not all patients had tissue biopsies before 
starting treatment, and therefore AR-V7 status may have changed 
before therapy. Secondly, patients without CTCs and therefore 
no AR-V7 result may be underrepresented in previous studies. In 
contrast to endocrine therapies, AR-V7 status did not associate 
with PSA response or progression-free survival in patients treated 
with docetaxel, as previously described (27, 28, 67). Interestingly, 
AR-V7–positive patients had shorter overall survival, suggesting 
that AR-V7 positivity may be associated with more aggressive dis-
ease, or this group of patients may have derived less benefit from 
treatment with further novel endocrine therapies. Taken together, 
these studies will be important to understand, as the landscape of 
CRPC changes as patients with de novo metastatic CSPC receive 
AA, and as we explore the potential use of AR-V7 to stratify patients 
to further AR-targeted therapies as they progress to CRPC.
The mechanisms by which AR splice variants are generat-
ed include genomic rearrangements and/or aberrant alternative 
mRNA splicing (22, 24, 32, 48, 68–71). AR-V7 generation has gen-
erally been attributed to aberrant splicing of AR pre-mRNA (72). 
This does not negate the fact that AR-FL increases under condi-
tions such as castration, and that this leads to the generation of 
AR-V7 (33, 46, 47). However, these data indicate that the mech-
anisms driving increased AR-FL expression and AR signaling in 
CRPC differ from those required for AR-V7 generation (72–76). 
Consistent with this, we demonstrate that although AR-FL and 
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AR-V7 immunoprecipitation
Cellular extracts were prepared from cumate-treated M12 cells 
expressing cumate-inducible AR-V7 lentivirus using the SparQcumate 
switch lentivector system (Systems Bioscience) as previously described 
(30). Precleared cell lysate was incubated with rabbit monoclonal anti–
AR-V7 antibodies (EPR15656, Abcam; or RM7, RevMAb Biosciences). 
Rabbit IgGs were used as a negative control. Immune complexes were 
collected using protein A/G Plus agarose beads and analyzed by immu-
noblotting as described above.
VCaP mouse xenograft models
All animal studies were performed in accordance with Beth Israel Dea-
coness Medical Center IACUC regulations (protocol 086-2016). VCaP 
mouse xenograft models have been previously described (83). Briefly, 
5 million VCaP cells in 100% Matrigel were injected subcutaneous-
ly into 6-week-old ICR scid mice (Taconic Biosciences). Xenografts 
were grown until 1,000 mm3; then mice were castrated. For AA- and 
E-resistant xenograft model, when castrated tumors exceeded 150% 
nadir volume, they were treated with AA (30 mg/kg) and E (50 mg/
kg). Tumors were biopsied before castration resistance, at castration 
resistance, and when resistant to AA and E therapy.
ICR/RMH and UW tissue samples
The Institute of Cancer Research and Royal Marsden Hospital (ICR/
RMH) CSPC and CRPC cohort was identified from men with CRPC 
treated at the Royal Marsden NHS Foundation Trust. The ICR/RMH 
CSPC cohort contained 63 patients with sufficient formalin-fixed, par-
affin-embedded (FFPE) diagnostic (archival) CSPC biopsies; all biop-
sies demonstrated adenocarcinoma and were from either prostate nee-
dle biopsies (47 patients), transurethral resection of the prostate (TURP; 
5 patients), transurethral resection of bladder tumor (TURBT; 1 patient), 
prostatectomy (8 patients), bone (1 patient), or rectal biopsy (1 patient). 
The ICR/RMH CRPC cohort contained 160 patients (which included 
all 63 patients in the CSPC cohort) with sufficient FFPE CRPC biopsies 
from metastatic biopsies of bone (81 patients), lymph node (51 patients), 
soft tissue (8 patients), liver (10 patients), TURP (7 patients), TURBT (1 
patient), or prostate (2 patients). All tissue blocks were freshly sectioned 
and were only considered for IHC analyses if adequate material was 
present. Demographic and clinical data for each patient were retrospec-
tively collected from the hospital electronic patient record system.
The University of Washington (UW) CSPC cohort was identified 
from men who received radical prostatectomy without neoadjuvant 
therapy. Tissue microarrays (TMAs) of FFPE tissue from primary pros-
tate acinar adenocarcinomas were generated. The tissue came from 
the radical prostatectomy samples of 295 patients, none of whom had 
received neoadjuvant therapy. The TMAs consisted of single cores of 
12 carcinomas, duplicate cores of 167 carcinomas, triplicate cores of 44 
carcinomas, and quadruplicate cores of 72 carcinomas. The UW CRPC 
cohort was identified from men who died of their prostate cancer and 
were part of the University of Washington Medical Center Prostate 
Cancer Rapid Autopsy Program (5). The cohort consisted of a TMA 
generated from biopsies of 133 metastases from 34 patients. Triplicate 
cores of the 133 metastases were placed on the TMA.
Immunohistochemistry
ICR/RMH CSPC and CRPC cohort. AR-V7 and AR-FL IHC was per-
formed as previously described (30, 31). Briefly, AR-V7 IHC was per-
from the same patient, indicating multiple resistance mechanisms 
in the same subject. These data suggest that multiple therapeutic 
modalities may be needed simultaneously to adequately reverse 
endocrine resistance in AR-V7–positive PC. Finally, AR-V7 protein 
expression associates with a unique gene signature that may drive 
transcriptional activity and PC progression. These results further 
confirm the importance of AR-V7 in CRPC biology and provide 
impetus for the development of novel therapeutic strategies that 
abrogate AR-V7 expression at the time of initial ADT in CSPC in 
order to prevent or delay development of CRPC and improve the 
outcome for patients with lethal PC.
Methods
Cell lines
LNCaP95 cells were provided by Alan K. Meeker and Jun Luo (Johns 
Hopkins University, Baltimore, Maryland, USA). 22Rv1 (CRL-2505), 
VCaP (CRL-2876), DU145 (HTB-81), M12 (a gift from Joy Ware, Vir-
ginia Commonwealth University, Richmond, Virginia, USA), and PC3 
(CRL-1345) cells were obtained from American Type Culture Collec-
tion. Doxycycline-inducible cell lines were created using lentiviral 
vectors in pLKO-Tet-On backbones targeting either GFP (shGFP; 
5′-GCAAGCTGACCCTGAAGTTCA-3′), AR-FL exon 8 (shAR-FL; 
5′-CCTGCTAATCAAGTCACACAT-3′), or AR-V7 cryptic exon 3 
(shAR-V7; 5′-GTAGTTGTGAGTATCATGA-3′), and lentiviral parti-
cles were produced as previously described (81, 82). Cells were infect-
ed with virus and selected with 1 μg/ml puromycin. shRNA expression 
was induced by treatment of cells with 1 μg/ml doxycycline for 72 
hours. All cell lines were grown in recommended media at 37°C in 5% 
CO2. Cell lines were tested for mycoplasma using the VenorGem One 
Step PCR Kit (Cambio) and short tandem repeat (STR) profiled.
Immunoblotting
ICR/RMH antibody validation. Cells were lysed with RIPA buffer 
(Pierce) supplemented with protease inhibitor cocktail (Roche). Pro-
tein extracts (20 μg) were separated on 7% NuPAGE Tris-Acetate gel 
(Invitrogen) by electrophoresis and subsequently transferred onto 
Immobilon-P PVDF membranes of 0.45 μm pore size (Millipore). Pri-
mary antibodies used were rabbit monoclonal anti–AR-V7 (1 in 1,000; 
RM7, RevMAb Biosciences), rabbit monoclonal anti–AR-V7 (1 in 
1,000; EPR15656, Abcam), and mouse monoclonal anti-vinculin (1 in 
200,000; V9131, Sigma-Aldrich) with species-specific secondary anti-
bodies conjugated to horseradish peroxidase. Chemiluminescence 
was detected on the Chemidoc Touch imaging system (Bio-Rad).
UW antibody validation. Cells were lysed with M-PER Mammalian 
Protein Extraction Reagent (Thermo Fisher Scientific) supplemented 
with Halt Protease Inhibitor and Halt Phosphatase Inhibitor Cock-
tail. Protein extracts (30 μg) were separated on 4%–15% Mini-PRO-
TEAN TGX Precast Protein Gel (Bio-Rad) by electrophoresis and 
subsequently transferred to a nitrocellulose membrane with an iBlot 
system. Primary antibodies used were rabbit monoclonal anti–AR-V7 
(1 in 2,000; RM7, RevMAb Biosciences), mouse monoclonal anti–AR 
N-terminus (1 in 2,000; AR441, Santa Cruz Biotechnology), and rabbit 
monoclonal anti-GAPDH (1 in 10,000; 2118, Cell Signaling Technol-
ogy). The specific signals were visualized on Blue Ultra Autorad Film 
(GeneMate) with species-specific secondary antibodies conjugated to 
horseradish peroxidase by chemiluminescence.
The Journal of Clinical Investigation   C L I N I C A L  M E D I C I N E
2 0 5jci.org   Volume 129   Number 1   January 2019
rithmically related to the OD. The OD is a measurement of absorbance 
and is linearly related to the amount of staining present. Automated 
scores for AR-V7 protein expression were reviewed and confirmed by 
a pathologist (L.D. True), and have been shown to correlate highly with 
manual scoring (Supplemental Figure 9 and refs. 84–86).
AR mutation and copy number analysis
AR mutations and AR copy number were determined for CRPC patient 
biopsies as previously described (87). 
RNA-Seq analysis
UW CRPC cohort. A set of 41 metastatic tumors from 24 men with 
CRPC were obtained through the University of Washington Prostate 
Cancer Donor Autopsy Program and used for transcript profiling by 
RNA-Seq, as described using frozen tissues (31, 88). RNA-Seq data are 
deposited in the Gene Expression Omnibus database under the acces-
sion number GSE118435. These tissues were from metastases where 
we had tissue available from the same block that had been used to 
spot the tissue microarray. Tissue microarray AR-V7 IHC scores were 
matched to mRNA samples by block ID. We then computed the Pearson 
correlation between AR-V7 expression (automated digital scoring) and 
gene mRNA expression (log2 counts per million), controlling for mul-
tiple testing using the cor.test and qvalue functions in R. There were 
487 genes with q value less than 0.05, 407 of which correlated with 
higher expression in AR-V7–expressing tumors. This 407-gene signa-
ture was independently tested in a set of 21 CRPC biopsies (ICR/RMH 
cohort; see below) and 122 CRPC transcriptomes (SU2C/PCF cohort; 
see below). AR-FL and AR-V7 mRNA expression in spliced reads per 
million mapped reads for 41 CRPC transcriptomes from the UW cohort 
were calculated as previously described (89). Junction reads spanning 
the AR exon 3 to exon 4 junction were used to estimate AR-FL–specific 
expression, while reads spanning the AR exon 3 to cryptic exon 3 junc-
tion were used to estimate AR-V7–specific reads, normalized by total 
spliced reads (genome-wide) to correct for sequencing depth.
ICR/RMH cohort. Twenty-one patients (from the SU2C/PCF con-
sortium) with AR-V7 protein expression by IHC and RNA-Seq analysis 
from the same biopsy were used. Data from 21 transcriptomes gener-
ated by the International Stand Up To Cancer/Prostate Cancer Foun-
dation (SU2C/PCF) Prostate Cancer Dream Team were download-
ed and reanalyzed (3). Paired-end transcriptome sequencing reads 
were aligned to the human reference genome (GRCh37/hg19) using 
TopHat2 (version 2.0.7). Gene expression, fragments per kilobase of 
transcript per million mapped reads (FPKM), was calculated using 
Cufflinks (90). For those genes identified in the UW CRPC cohort, 
association between nuclear AR-V7 protein expression (IHC) and each 
gene mRNA expression (RNA-Seq) from the same biopsy was deter-
mined using Pearson correlation coefficient.
SU2C/PCF cohort. Data from 122 CRPC transcriptomes generated 
by the International Stand Up To Cancer/Prostate Cancer Foundation 
(SU2C/PCF) Prostate Cancer Dream Team were downloaded and rean-
alyzed as described above. For those genes identified in the UW CRPC 
cohort, association between AR-V7 mRNA expression and each gene 
mRNA expression was determined using Pearson correlation coefficient.
Pathway enrichment analysis
Of the 407 genes positively associated with higher AR-V7 levels with 
a q value less than 0.05 in the UW CRPC cohort (described above), 59 
formed using recombinant rabbit monoclonal anti–AR-V7 antibody 
(Clone RM7, RevMAb Biosciences). Biopsies were first deparaffinized 
before antigen retrieval by microwaving (in Tris/EDTA buffer, pH 8.1) 
for 18 minutes at 800 W, and anti–AR-V7 antibody (1:500 dilution in 
Dako REAL diluent, Agilent Technologies) was incubated with tissue 
for 1 hour at room temperature. After washes, bound antibody was 
visualized using Dako EnVision Detection System (Agilent Technolo-
gies). Sections were counterstained with hematoxylin. Cell pellets from 
22Rv1 (positive) and PC3 (negative) were used as controls. Rabbit IgGs 
were used as a further negative control. AR-FL IHC was performed 
using mouse monoclonal anti-AR antibody (AR441, Agilent Technol-
ogies). Biopsies were first deparaffinized before antigen retrieval using 
pH 8.1 Tris/EDTA solution heated in a water bath, and anti-AR anti-
body (1:1,000 dilution in Dako REAL diluent, Agilent Technologies) 
was incubated with tissue for 1 hour at room temperature. After wash-
es, bound antibody was visualized using Dako EnVision Detection Sys-
tem (Agilent Technologies). Sections were counterstained with hema-
toxylin. Cell pellets from VCaP (positive) and PC3 (negative) were used 
as controls. Mouse IgGs were used as a further negative control.
UW CSPC and CRPC cohort. Briefly, AR-V7 IHC was performed 
using recombinant rabbit monoclonal anti–AR-V7 antibody (Clone 
RM7, RevMAb Biosciences). Deparaffinization, antigen retrieval (Cell 
Conditioner 1, Ventana Medical Systems), and immunostaining were 
performed on the Ventana Benchmark automated stainer (Ventana 
Medical Systems). Sections were incubated for 2 hours at 37°C with 
anti–AR-V7 antibody (1:50 in antibody diluent; Ventana Medical Sys-
tems). After washes, bound antibody was visualized using Ventana 
Optiview DAB detection kit (Ventana Medical Systems). Sections were 
counterstained with hematoxylin. Controls were sections of a TMA 
made of cell lines known to express AR-FL and/or AR-V7 (LNCaP, 
22Rv1, VCaP) or known not to express AR-FL or AR-V7 (DU145, PC3, 
M12) and cells engineered to stably express both AR-FL (M12 AR-FL) 
and AR-V7 (M12 AR-V7) by transfection.
IHC quantification
ICR/RMH CSPC and CRPC cohort. AR-V7 and AR-FL protein expres-
sion was determined for each case by a pathologist (D.N. Rodrigues) 
blinded to clinical data using the modified H score (HS) method, a 
semiquantitative assessment of staining intensity that reflects antigen 
concentration. HS was determined according to the formula: ([% of 
weak staining] × 1) + ([% of moderate staining] × 2) + ([% of strong 
staining] × 3), yielding a range from 0 to 300 (84).
UW CSPC and CRPC cohort. AR-V7 protein expression in the UW 
CSPC cohort was determined for each case by a pathologist (L.D. True) 
as described above. AR-V7 protein expression in the UW CRPC cohort 
was determined using automated digital scoring as follows: TMA 
slides were scanned with an Aperio ScanScope (Leica Biosystems) at 
×40 (0.25 μm/pixel). Using Aperio ImageScope software, the AR-V7–
stained TMA slides were annotated to create regions of interest (ROIs) 
for analysis. Quantitative image analysis of the annotated ROIs was 
performed using Aperio Brightfield Image Analysis Toolbox software 
(Leica Biosystems). The analysis data for each TMA spot were extracted 
into Microsoft Excel for further analysis. The quantitative analysis data 
for each TMA spot included total numbers and percentages of nuclei 
(positive and negative), average positive intensity, average positive OD, 
and area of analysis. The intensity is a measurement of the light trans-
mission, or brightness, of the positive staining in the nuclei and is loga-
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Study approval
All animal studies were performed in accordance with Beth Israel 
Deaconess Medical Center (Boston, Massachusetts, USA) IACUC reg-
ulations (protocol 086-2016). All patients treated at the Royal Mars-
den NHS Foundation Trust had provided written informed consent 
and were enrolled in institutional protocols approved by the Royal 
Marsden NHS Foundation Trust Hospital (London, United Kingdom) 
ethics review committee (reference 04/Q0801/60). All procedures 
involving human subjects at the University of Washington (Seattle, 
Washington, USA) and Fred Hutchinson Cancer Research Center 
(Seattle, Washington, USA) were approved by the Institutional Review 
Board at those institutions.
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were found to be positively associated and significant with P less than 
0.05 in either the ICR/RMH cohort or the SU2C/PCF cohort. The 
UpSetR R package was used to plot overlap between cohorts. Pathway 
overrepresentation analysis of the 407- and 59-gene sets was conduct-
ed using the Compute Overlaps tool with MSigDB v6.2 (H, Hallmark; 
CP, Canonical Pathways; C4, Computational Gene Sets; C5, GO; and 
C6, Oncogenic Pathways) (49, 50, 91).
Statistics
All statistical analyses were conducted using Stata v13.1 or Graph-
Pad Prism v6 and are indicated within all figures and tables. H scores 
(HSs) were reported as median values with interquartile range. For 
the ICR/RMH CSPC and CRPC cohort, Mann-Whitney test was used 
to compare differences in nuclear AR-V7 protein expression levels. 
Spearman’s rank correlation coefficient was used to determine the 
association between nuclear AR-V7 protein expression and timing of 
CRPC biopsy after the starting of AA or E therapy. Nonparametric 
equality-of-medians test was used to determine the difference in 
nuclear AR-V7 protein expression between metastatic sites. Wilcox-
on matched-pairs signed-rank test was used to determine the differ-
ence in nuclear AR-V7 protein expression as VCaP mouse xenografts 
progressed from castration sensitive through castration resistant to 
AA/E resistant. Spearman’s rank correlation coefficient was used to 
determine associations between AR-FL and AR-V7 mRNA expres-
sion, total AR-V7 and total AR-FL protein expression, total AR-V7 
protein expression and AR copy number, total AR-FL protein expres-
sion and AR copy number, nuclear AR-V7 and nuclear AR-FL pro-
tein expression, and OD and HS quantification for nuclear AR-V7 
expression. Fligner-Killeen’s and Levene’s tests for homogeneity of 
variances between tumors and within tumors were performed in R 
using the fligner.test and leveneTest functions. Patients’ responses 
to AR-targeted therapy (AA or E) before and after chemotherapy 
and docetaxel were determined. For each therapy, PSA nadir was 
calculated as the lowest PSA level on therapy, and 12-week PSA 
response was calculated as the percentage change in PSA between 
the start of therapy (baseline) and 12 weeks of treatment (or clos-
est available PSA reading). Time to PSA progression was defined as 
time from start of therapy to first PSA increase that is at least 25% 
and at least 2 μg/l above the PSA nadir. Time to clinical/radiolog-
ical progression was defined as time from start of therapy to doc-
umented radiological progression or clinical progression (including 
change of therapy, addition of investigational medicinal product, or 
stopping of treatment). Overall survival was defined as time from 
start of therapy to date of death or last follow-up/contact. Patients’ 
baseline characteristics and clinical outcomes were compared by 
positive (nuclear AR-V7 HS >10) or negative (nuclear AR-V7 HS 
≤10) AR-V7 status. Patients’ baseline characteristics were compared 
using Fisher’s exact test, Student’s t tests (2-tailed), and Wilcoxon 
rank-sum test as indicated. The 50% PSA nadir and 12-week 50% 
PSA response rates were compared using Fisher’s exact test. Nucle-
ar AR-V7 expression by 50% PSA response rate was compared using 
Mann-Whitney U test. Median time to PSA progression, time to 
clinical/radiological progression, and overall survival were estimat-
ed using the Kaplan-Meier method. Association with AR-V7 status 
(positive vs. negative) was tested using univariable Cox proportional 
hazards models. For all statistical analysis, a P value less than 0.05 
was considered to be statistically significant.
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